Abpro Holdings, Inc.

AI-generated fair value estimate for this company.

Method: Going-concern-adjusted net-asset-value estimate: clinical-stage biotech (5.90M shares, US$1.19M market cap) with no product revenue; assumed minimal residual net cash after burn plus a small discounted allowance for the early-stage ABP-102 HER2 antibody program and DiversImmune/MultiMab platform, for a total equity value of roughly $0.3M

Reasoning: With no revenue, a market cap already near cash value, and a single early-stage clinical asset, a discounted-cash-flow model would require speculative peak-sales assumptions this company hasn't yet earned; a conservative liquidation/NAV-style estimate better reflects the actual economic backing available to shareholders today